Voyager Acquisition Corp Unit (VACHU)

VERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for treating autoimmune and chronic immune diseases, combining their unique technology platforms.